IPX203 represents a groundbreaking advancement in Parkinson's disease (PD) treatment with its novel oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules. Unlike existing options...
Frexalimab (SAR441344) is a novel anti-CD40L antibody in development, designed to inhibit the CD40/CD40L pathway, a crucial element in activating both adaptive and innate immune responses. Its distinctive mode of action targets neuroinflammation in multiple sclerosis, offering potential benefits for both acute and...
Find MoreAXS-07, a cutting-edge oral solution, blends MoSEIC meloxicam and rizatriptan, offering rapid absorption. It ingeniously inhibits CGRP release, counteracting vasodilation, and curbing neuroinflammation and pain transmission for enhanced relief. AXS-07 demonstrates superior efficacy in swiftly alleviating migrai...
Find MoreUB-312 represents a promising avenue in Parkinson's disease (PD) treatment by focusing on pathological forms of alpha-synuclein (aSyn), a key protein associated with the progression of synucleinopathies. Unlike conventional approaches, UB-312 aims to elicit antibodies that specifically recognize and neutralize the...
Find MoreZEPOSIA (ozanimod), a breakthrough approved in March 2020 for Relapsing Forms of Multiple Sclerosis (RMS), utilizes oral sphingosine 1-phosphate (S1P) receptor modulation to impede lymphocyte migration, offering a novel approach in multiple sclerosis treatment. ENLIGHTEN (NCT04140305) explores ozanimod's impact...
Find MoreNeuroDerm's ND0612 introduces a pioneering approach to Parkinson's disease management with its self-administered continuous subcutaneous infusion of levodopa/carbidopa. Unlike traditional oral formulations, ND0612 bypasses the gastrointestinal tract, offering increased bioavailability and potentially more reliable...
Find MoreEculizumab (SOLIRIS) and ravulizumab (ULTOMIRIS) are two approved therapies for the treatment for adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor antibody-positive. The findings presented by Alexion, AstraZeneca Rare Disease unveil a remarkable decline in Myasthenia G...
Find MoreEfgartigimod (VYVGART/VYVGART Hytrulo) is a prescription medicine for the treatment of gMG in adults who are positive for antibodies directed toward a protein called acetylcholine receptor (anti-AChR antibody positive). It is designed as a first-in-class investigational antibody fragment to target the neonatal Fc ...
Find MoreP2B001, a novel once-daily combination therapy, uniquely merges extended-release pramipexole and rasagiline in low doses, targeting Parkinson's Disease (PD) with enhanced efficacy and minimized side effects. The analysis presented by Pharma Two B highlighted P2B001's impressive safety and tolerability profile c...
Find MoreEfgartigimod PH20 is a combination subcutaneous (SC) infusion that contains efgartigimod alfa and hyaluronidase which may be used to improve muscle weakness in adults with generalized myasthenia gravis (gMG) who are anti-AChR antibody positive. The interim results presented by Argenx highlighted notable efficac...
Find MoreWith worldwide dissemination and now over 9 million cases and nearly 500,000 deaths recorded, the ef.....
Find MoreMyocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or compl.....
Find MoreA rare neurological disorder characterized by progressive weakness and impaired sensory function in .....
Find MoreA chronic pain condition, Complex Regional Pain Syndrome (CRPS) often affects one limb and is believ.....
Find MoreImmunity is a major concern in the present times, and consumers have increased their focus on boosti.....
Find MoreLyme disease is a vector-borne infectious disease that spreads primarily by the bite of a tick (also.....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.